Czech National Bank increased its position in ResMed Inc. (NYSE:RMD – Free Report) by 6.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,931 shares of the medical equipment provider’s stock after purchasing an additional 1,936 shares during the period. Czech National Bank’s holdings in ResMed were worth $7,307,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. OFI Invest Asset Management bought a new position in ResMed during the 2nd quarter valued at about $32,000. BOK Financial Private Wealth Inc. bought a new position in ResMed during the 1st quarter valued at about $35,000. Versant Capital Management Inc lifted its stake in ResMed by 196.7% during the 2nd quarter. Versant Capital Management Inc now owns 181 shares of the medical equipment provider’s stock valued at $35,000 after acquiring an additional 120 shares during the period. Financial Connections Group Inc. bought a new position in ResMed during the 2nd quarter valued at about $37,000. Finally, Riverview Trust Co bought a new position in ResMed during the 1st quarter valued at about $42,000. Institutional investors own 54.98% of the company’s stock.
Insider Buying and Selling at ResMed
In other news, insider Justin Leong sold 48,000 shares of ResMed stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $217.07, for a total value of $10,419,360.00. Following the completion of the transaction, the insider now owns 18,741 shares in the company, valued at approximately $4,068,108.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Justin Leong sold 48,000 shares of ResMed stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $217.07, for a total value of $10,419,360.00. Following the completion of the transaction, the insider now owns 18,741 shares in the company, valued at approximately $4,068,108.87. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brett Sandercock sold 1,000 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $212.16, for a total value of $212,160.00. Following the transaction, the chief financial officer now owns 89,056 shares of the company’s stock, valued at approximately $18,894,120.96. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 119,614 shares of company stock worth $27,135,217 over the last 90 days. 1.21% of the stock is owned by insiders.
Wall Street Analyst Weigh In
View Our Latest Research Report on ResMed
ResMed Trading Up 0.4 %
ResMed stock opened at $237.93 on Friday. The firm has a 50 day moving average of $235.54 and a 200 day moving average of $213.84. The firm has a market capitalization of $34.92 billion, a price-to-earnings ratio of 36.55, a P/E/G ratio of 2.11 and a beta of 0.69. ResMed Inc. has a 12-month low of $132.24 and a 12-month high of $255.18. The company has a current ratio of 2.59, a quick ratio of 1.69 and a debt-to-equity ratio of 0.14.
ResMed (NYSE:RMD – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.03 by $0.05. ResMed had a net margin of 21.79% and a return on equity of 25.00%. The business had revenue of $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same period last year, the firm posted $1.60 EPS. The company’s revenue was up 6.9% on a year-over-year basis. As a group, research analysts predict that ResMed Inc. will post 9.02 earnings per share for the current year.
ResMed Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Thursday, September 19th. Stockholders of record on Thursday, August 15th were given a dividend of $0.53 per share. This is an increase from ResMed’s previous quarterly dividend of $0.48. This represents a $2.12 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend was Thursday, August 15th. ResMed’s dividend payout ratio is currently 32.57%.
ResMed Company Profile
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.
See Also
- Five stocks we like better than ResMed
- What is the Shanghai Stock Exchange Composite Index?
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- What is an Earnings Surprise?
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Differences Between Momentum Investing and Long Term Investing
- 3 Small-Cap Stocks Ready to Deliver Significant Growth
Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD – Free Report).
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.